TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
The scientist Marta M. Alonso from Spain recently reported their finding on the potential of TIM-3 (HAVCR2) in targeting Diffuse Intrinsic Pontine Glioma (DIPG).
TIM-3 is highly expressed in DIPGs In this study, researchers investigate the potential of targeting TIM-3, an immune checkpoint molecule, as a therapeutic strategy for Diffuse Intrinsic Pontine Glioma (DIPG), an aggressive brain stem tumor with a high mortality rate.